Main menu

Nanogen has finished beta-testing its ASRs for mutations in the CFTR gene and has begun a controlled launch of the products, which are associated with cystic fibrosis.

Nanogen also released a 3-SNP ASR for mutations in the HFE gene, which are associated with hereditary hemachromatosis. The firm also began beta-testing its Assay Tool Box product, which is expected to roll out by the end of the month.

Two other products began beta-testing, according to Nanogen: a test for beta-thalassemia and a multiplex ASR for Factor V and Factor II.

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.